Burning Rock Biotech Limited (BNR)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Central Laboratory Channel	159.99M	175.65M	232.81M	314.77M	319.35M
In-Hospital Channel	224.04M	224.49M	188.70M	175.30M	165.12M
Pharma Research and Development Channel	155.54M	115.68M	115.92M	73.17M	23.39M
Total	539.57M	515.82M	537.44M	563.24M	507.86M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Overseas	100.93M	100.09M	61.24M	-	-
Mainland China	438.64M	415.73M	476.19M	-	-
People’s Republic of China (PRC)	-	-	-	553.30M	504.05M
United States	-	-	-	9.93M	3.81M
Total	539.57M	515.82M	537.44M	563.24M	507.86M

Data Source: S&P Global Market Intelligence Last updated: Apr 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error